Home  /  Resource Library  /  Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

ASH 2020: Long term results of a study examining tafasitamab combined with lenalidomide for treatment of high risk relapsed DLBCL.